CD19+ B cell numbers predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
Schiavetti, I.; Barcellini, L.; Lapucci, C.; Tazza, F.; Cellerino, M.; Capello, E.; Franciotta, D.; Inglese, M.; Sormani, M. P.; Uccelli, A.; Laroni, A.
Show abstract
Treatment with fingolimod for multiple sclerosis (MS) reduces the efficacy of COVID-19 vaccination. We evaluated by a multivariate linear regression model whether main lymphocyte subsets and demographic feature correlated to the subsequent increase in anti-SARS-CoV2 antibodies following the third dose of COVID-19 vaccination in fingolimod-treated MS patients. We found that number and proportion of peripheral blood CD19+ B lymphocytes before the third dose of vaccination in MS patients treated with fingolimod, predict the subsequent increase of anti-SARS-CoV2 antibodies (respectively p = 0.013; p = 0.015). This work suggests that evaluating the numbers of CD19+ B cells may be important to identify patients at risk of not producing SARS-CoV-2 antibodies, with possible reduced protection from COVID-19.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Humoral and cellular immune responses to SARS CoV-2 vaccination in Persons with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments 96%
- Response to COVID-19 booster vaccinations in seronegative people with MS. 96%
- Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy 94%
Similar papers in this journal
- Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies 95%
- Frequency and Potential Risk Factors Associated with the Development of Asymptomatic T2 Hyperintense Cervical Spine Lesions on MRI in Patients with Relapsing-Remitting Multiple Sclerosis 92%
- Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical outcomes in multiple sclerosis: a retrospective cross-sectional study 92%
Similar papers in this journal
- SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular immune responses in multiple sclerosis patients receiving fingolimod 92%
- Genetic subtypes predict multiple sclerosis severity and response to treatment 90%
- Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis 89%
Similar papers in this journal
- COVID-19 vaccine response in people with multiple sclerosis 95%
- SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab 95%
- Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study 91%
Similar papers in this journal
- Current status and future opportunities in modeling Multiple Sclerosis clinical characteristics 91%
- Experimental Autoimmune Encephalomyelitis Causes Skeletal Muscle Dysfunction in Mice 91%
- The Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis cohort population structure and disease etiology 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.